Grünwalder Str. 1 81547 München info@cavitau.de

Inventor and historical development

Startseite About CaviTAU® Inventor and historical development

CaviTAU® was developed under the medical direction of Dr Johann Lechner (PhD-UCN), a doctor of medical dentistry, in order to visualise reduced mineral density in the jawbone.
The technical development was carried out by qinno, Argelsrieder Feld 11; 82234 Weßling, Germany, led by Mr Zimmermann/Mr Falcke. CaviTAU® is protected by international patents: PCT/EP2018/084199. CaviTAU® is sponsored by Bayern Innovativ (www.bayern-innovativ.de), an initiative of the Bavarian Ministry of Economic Affairs (download subsidy vouchers). The use of CaviTAU® is scientifically and professionally supported by the ICOSIM association of therapists (International College of Maxillo-Mandibular Osteoimmunology e.v.). Members of the association receive preferential treatment in the form of documents and discounts. For more information, go to www.icosim.de CaviTAU® is a Class I medical device in accordance with MDD 93/42/EEC and is distributed by the company:

CaviTAU® GmbH Grünwalder Str. 1 81547 München +49 89 90 42 17 62 info@cavitau.de www.cavitau.de

Historical development

Over the last 10 years, there have been numerous scientific publications on the diagnostic applications of ultrasound in dentistry. As early as 2002, the “CAVITAT” ultrasonograph, U.S. Patent #6030221, was put on the market in the USA for practical implementation by the American company Cavitat® Medical Technologies. Cavitat® was approved by the FDA (Ref#K011147*CSA Ref#37968) for diagnosing reduced mineral density in the jawbone. Cavitat Medical Technologies’ ongoing litigation with Aetna Insurance Company ended in a settlement in which a US federal judge sentenced Aetna to pay several million US $. Production of Cavitat® ceased in 2011, and since 2015 the product has not been available. This meant that, until the current series development of CaviTAU®, there were no ultrasound products on the market capable of measuring bone density in the jaw. CaviTAU® brings with it significant improvements in terms of measurement and applications.

Relevant scientific studies, in particular at the Mainz University Clinic by Prof. Al-Nawas and Prof. Klein (Al-Nawas, B., Klein, M.O., Goetz, H., Vaterod, J.,Dushner, H., Grotz, K.A., & Kann, P.H. (2008) Dental implantation: ultrasound transmission velocity to evaluate critical bone quality- animal mode. Ultraschall in der Medizin 29: 302-307 and Klein, M.O., Grotz, K.A., Manefeld, B., Kann, P.H. & Al-Nawas, B. (2008) Ultrasound transmission velocity for non-invasive evaluation of jaw bone quality in vivo prior to dental implantation. Ultrasound in Medicine & Biology 34: 1966-1971.) led to the S3 guideline “Odontogenic Infections” (“Odontogene Infektionen”) WMF register number: 007-006, version: September 2016, valid until: September 2021 from the German Society of Oral and Maxillofacial Surgery (Deutsche Gesellschaft für Mund-, Kiefer- und Gesichtschirurgie, DGMKG) and the German Society of Dental, Oral and Maxillofacial Surgery (Deutsche Gesellschaft für Zahn-, Mund- und Kieferheilkunde, DGZMK). This guideline contains evidence-based recommendations for the imaging of odontogenic infections with a tendency to spread: “Diagnosis can be completed through an ultrasound scan (recommendation grade 0: LoE IIIb [120]; LoE IV [121]; LoE IIIb [122]). Consensus strength: 17/17: 17/17: Ultrasound scans provide a simple and efficient way to detect necrolysis in odontogenic infections, and to assess the potential spread of odontogenic infections.”

Comparison of CaviTAU® vs Cavitat

The new and improved CaviTAU® in comparison to the obsolete Cavitat measurement device

More informations about CaviTAU®